Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.

Abstract

Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non-Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell-engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.

DOI: 10.1126/science.1158545
02004006002008200920102011201220132014201520162017
Citations per Year

3,193 Citations

Semantic Scholar estimates that this publication has 3,193 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Bargou2008TumorRI, title={Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.}, author={Ralf Bargou and Eugen Leo and Gerhard Zugmaier and Matthias Klinger and Mariele Goebeler and Stefan Knop and Richard Noppeney and Andreas Viardot and Georg Hess and Martin Schuler and Hermann Einsele and Christian Brandl and Andreas Wolf and Petra Kirchinger and Petra Klappers and Margit Schmidt and Gert Riethm{\"{u}ller and Carsten Reinhardt and Patrick A Baeuerle and Peter Kufer}, journal={Science}, year={2008}, volume={321 5891}, pages={974-7} }